Who are Abrysvo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Beyfortus, RSVpreF 120 µg, Liquid Palivizumab, RSVpreF, RSV Vaccine, AREXVY, ABRYSVO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abrysvo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Abrysvo — Competitive Intelligence Brief

Abrysvo (abrysvo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

marketed vaccine RSV Infectious Disease Live · refreshed every 30 min

Target snapshot

Abrysvo (abrysvo) — Pfizer. ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abrysvo TARGET	abrysvo	Pfizer	marketed	vaccine	RSV
Beyfortus	NIRSEVIMAB	AstraZeneca	marketed	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	RSV	2023-01-01
RSVpreF 120 µg	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein
Liquid Palivizumab	Liquid Palivizumab	MedImmune LLC	marketed	Monoclonal antibody (RSV F protein inhibitor)	RSV F (fusion) protein
RSVpreF	rsvpref	Pfizer	marketed	Monoclonal antibody	RSV F protein
RSV Vaccine	RSV Vaccine	Pfizer	marketed	Recombinant protein subunit vaccine	Respiratory syncytial virus (RSV) fusion (F) glycoprotein
AREXVY, ABRYSVO	AREXVY, ABRYSVO	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Recombinant glycoprotein vaccine	RSV fusion (F) glycoprotein, prefusion conformation

Recent regulatory actions (last 90 days)

2026-04-07 — Beyfortus · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abrysvo — Competitive Intelligence Brief. https://druglandscape.com/ci/abrysvo. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab